Bei der vorliegenden Arbeit handelt es sich um eine experimentell durchgeführte Charakterisierung von CD11c-positiven Zellen des Gehirns im direkten Vergleich zu CD11c-positiven Zellen aus Lunge, Leber und Milz. Mittels Konfokal- und Fluoreszenzmikroskopie wurde die Existenz von intraparenchymalen Zellen nachgewiesen, welche den Zellmarker für Dendritische Zellen CD11c exprimieren. Durch die Etablierung einer einheitlichen Isolierungsmethode von CD11c-positiven mononukleären Zellen aus dem Gehirn, Milz, Lunge und Leber, war es uns möglich, diese mittels Durchflusszytometrie, auf die Expression wichtiger Marker für mononukleäre Zellen zu untersuchen und phänotypisch miteinander zu vergleichen. Durch diese Zellanalysen zeigten wir, dass CD11c-positive Zellen des Gehirns sowohl aufgrund ihrer spezifischen CD45-Expression, als auch durch die Expression von CD11b einen Mikrogliaphänotyp aufwiesen. Dabei konnten wir beobachten, dass CD11c-positive Zellen aus dem Gehirn einzigartig in der Eigenschaft ihrer geringen Major Histocompatibility Complex (MHC)-II-Expression sind. Mit Hilfe einer transgenen Mauslinie, welche unter dem Promotor von MHC-II das grün-fluoreszierende Protein (GFP) exprimiert, konnten wir nachweisen, dass Mikroglia selbst in der Umgebung von MHC-II-positiven Zellen, kultiviert auf Schnittkulturen der Milz, ihre MHC-II-Negativität behalten. Im Vergleich dazu adaptierten sich MHC-II-positive Splenozyten, kultiviert auf Schnittkulturen vom Hippocampus, an die neue Umgebung und verringerten die Expression von MHC-II. Unsere Daten lassen also die Schlussfolgerung zu, dass sich CD11c-positive Mikroglia hinsichtlich ihrer Expression von MHC-II intrinsisch von CD11c-positiven Zellen anderer Organe unterscheiden. Ebenso scheinen auch lokale Faktoren im Gehirn dazu beizutragen, die Expression von MHC-II unter physiologischen Bedingungen wirkungsvoll zu unterdrücken.

Prion diseases are fatal infectious neurodegenerative disorders hypothesised to be caused by misfolding of the prion protein. Following prion infection, the infectious agent is sequestered to and replicates upon follicular dendritic cells (FDC) within lymphoid follicles prior to neuroinvasion. The mechanism of transport of the prion infectious agent from the site of infection to FDC is unknown. One of the postulated routes of transport is the specific migration of antigen presenting cells (APC) to FDC. APC specifically capture antigenic material and transport and present that material to effector cells and FDC in order to generate an appropriate acquired immune response. FDC reside within the B-cell follicle of secondary lymphoid organs. FDC organise and maintain the B-cell follicular structure by secretion of the chemokine CXCL13 which stimulates chemotactic movement of cells which express the CXCR5 receptor, e.g. B cells. Dendritic cells are specialised APC that are commonly characterised by their expression of CD11c. Transport of the prion infectious agent from the site of infection to FDC was observed to be blocked or severely delayed following depletion of CD11c+ cells. To determine whether CD11c+ cells acquire prions and subsequently deliver them to the FDC, the chemokine receptor CXCR5 was depleted from CD11c+ cells using a conditional transgenic mouse model. These mice were characterised for normal lymphoid organogenesis and monitored for their responses to oral infection with either prions or intestinal helminths. Data in this thesis show that the CD11c-mediated depletion of CXCR5 resulted in a delay in peripheral prion pathogenesis after oral exposure and significantly reduced disease susceptibility. These data suggest that efficient prion transport to FDC requires delivery by APC and is potentially mediated by CXCR5 chemotaxis. Following oral exposure to the intestinal helminth (Trichuris muris) CD11c-mediated depletion of CXCR5 prevented the establishment of a protective TH2 response. As a consequence the mice mounted a TH1-dominated response and were unable to clear the infection. These data also confirm that the effective generation of TH2 responses to oral helminth infection also requires APC localisation to B-cell follicles via CXCR5.

Bei der vorliegenden Arbeit handelt es sich um eine experimentell durchgeführte Charakterisierung von CD11c-positiven Zellen des Gehirns im direkten Vergleich zu CD11c-positiven Zellen aus Lunge, Leber und Milz. Mittels Konfokal- und Fluoreszenzmikroskopie wurde die Existenz von intraparenchymalen Zellen nachgewiesen, welche den Zellmarker für Dendritische Zellen CD11c exprimieren. Durch die Etablierung einer einheitlichen Isolierungsmethode von CD11c-positiven mononukleären Zellen aus dem Gehirn, Milz, Lunge und Leber, war es uns möglich, diese mittels Durchflusszytometrie, auf die Expression wichtiger Marker für mononukleäre Zellen zu untersuchen und phänotypisch miteinander zu vergleichen. Durch diese Zellanalysen zeigten wir, dass CD11c-positive Zellen des Gehirns sowohl aufgrund ihrer spezifischen CD45-Expression, als auch durch die Expression von CD11b einen Mikrogliaphänotyp aufwiesen. Dabei konnten wir beobachten, dass CD11c-positive Zellen aus dem Gehirn einzigartig in der Eigenschaft ihrer geringen Major Histocompatibility Complex (MHC)-II-Expression sind. Mit Hilfe einer transgenen Mauslinie, welche unter dem Promotor von MHC-II das grün-fluoreszierende Protein (GFP) exprimiert, konnten wir nachweisen, dass Mikroglia selbst in der Umgebung von MHC-II-positiven Zellen, kultiviert auf Schnittkulturen der Milz, ihre MHC-II-Negativität behalten. Im Vergleich dazu adaptierten sich MHC-II-positive Splenozyten, kultiviert auf Schnittkulturen vom Hippocampus, an die neue Umgebung und verringerten die Expression von MHC-II. Unsere Daten lassen also die Schlussfolgerung zu, dass sich CD11c-positive Mikroglia hinsichtlich ihrer Expression von MHC-II intrinsisch von CD11c-positiven Zellen anderer Organe unterscheiden. Ebenso scheinen auch lokale Faktoren im Gehirn dazu beizutragen, die Expression von MHC-II unter physiologischen Bedingungen wirkungsvoll zu unterdrücken.

Em alguns casos, pacientes que sobreviveram a uma sepse grave podem desenvolver um quadro de imunossupressão, caracterizado pela expansão dos linfócitos T reguladores (Tregs). Porém, apesar de inúmeros avanços, os mecanismos associados à expansão das Tregs, ainda não estão completamente esclarecidos. Nesse sentido, trabalhos recentes demonstraram que a atividade da enzima Indoleamina 2,3-Dioxigenase (IDO), responsável pela formação da quinurenina a partir da degradação do aminoácido essencial triptofano, está relacionada à diferenciação das Tregs e com o desenvolvimento de um quadro de tolerância. Dessa forma, o objetivo deste estudo foi investigar o papel da IDO no desenvolvimento da imunossupressão induzida pela sepse. Os resultados demonstraram um aumento da expressão proteica e da atividade enzimática da IDO no baço de camundongos que sobreviveram à sepse grave. Para avaliar o desenvolvimento da imunossupressão, os camundongos foram desafiados com células do melanoma B16-F10. A inibição farmacológica da IDO promoveu redução do crescimento tumoral nos camundongos que sobreviveram à sepse, por um mecanismo dependente da redução na diferenciação das Tregs e das células C11b+ Ly6G+ no baço e da ativação de células CD8+ produtoras de IFN- ?, no linfonodo drenate da região tumoral. Adicionalmente, foi demonstrado que, o receptor de hidrocarbonetos de arila (AhR) está associado ao aumento da expressão da IDO, nos camundongos que sobreviveram à sepse. Ainda, os resultados demonstraram que células CD11C+ são as principais responsáveis por expressar a IDO no baço de camundongos que sobreviveram à sepse. Por fim, células CD11C+ isoladas do baço de camundongos que sobreviveram a sepse, foram mais efetivas em induzir a diferenciação das Tregs quando comparadas a células CD11C+ provenientes de camundongos naive. Em conjunto, os resultados sugerem que a ativação do AhR pela quinurenina é importante para expressão da IDO nas células CD11C+ encontradas no baço de camundongos que sobreviveram à sepse, o que por sua vez, está associado com a expansão das Tregs e com o desenvolvimento do quadro de imunossupressão. / Immunosuppression has been shown to be one long-term sequels of severe sepsis, which is mainly characterized by the expansion of regulatory T cells (Tregs). However, the mechanisms underlying Tregs expansion after sepsis remain poor understood. Indoleamine 2,3-dioxygenase (IDO), an enzyme that initiates the kynurenine pathway of tryptophan degradation, has been implicated in promoting Tregs generation. Therefore, we propose to investigate the role of IDO in the development of sepsis-induced immunosuppression. The results presented here demonstrated that there is an increase in both IDO protein expression and IDO enzymatic activity in spleen of sepsis-surviving mice. Employing a melanoma mouse model as a second challenge in sepsis-surviving mice, we found that pharmacological inhibition of IDO suppressed the enhanced tumor growth observed in sepsis-surviving mice. Importantly, inhibition of IDO decreased the expansion of Tregs in sepsis-surviving mice, leading to reduced CD11b+ Ly6G+ cells frequency in spleen and activation of INF-? production by CD8+ in draining lymph, after tumor challenge. Moreover, the results suggest that aryl hydrocarbon receptor (AhR) is associated with increased IDO expression found in sepsis-surviving mice. Furthermore, we identified that a CD11C+ population of cells are expressing IDO in spleen of sepsis surviving mice. In addition, CD11C+ cells isolated from spleen of sepsis-surviving mice, presented a higher capacity to induce a regulatory phenotype in naïve CD4+ CD25- T than CD11C+ isolated from naïve mice. Taken together, our results suggest that AhR activation by kynurenine during acute phase of sepsis is important to IDO expression in a specific CD11C+. This new sepsis-induced CD11C+ IDO+ population is important to Treg cells expansion and immunosuppression development in sepsis-surviving mice.

Em alguns casos, pacientes que sobreviveram a uma sepse grave podem desenvolver um quadro de imunossupressão, caracterizado pela expansão dos linfócitos T reguladores (Tregs). Porém, apesar de inúmeros avanços, os mecanismos associados à expansão das Tregs, ainda não estão completamente esclarecidos. Nesse sentido, trabalhos recentes demonstraram que a atividade da enzima Indoleamina 2,3-Dioxigenase (IDO), responsável pela formação da quinurenina a partir da degradação do aminoácido essencial triptofano, está relacionada à diferenciação das Tregs e com o desenvolvimento de um quadro de tolerância. Dessa forma, o objetivo deste estudo foi investigar o papel da IDO no desenvolvimento da imunossupressão induzida pela sepse. Os resultados demonstraram um aumento da expressão proteica e da atividade enzimática da IDO no baço de camundongos que sobreviveram à sepse grave. Para avaliar o desenvolvimento da imunossupressão, os camundongos foram desafiados com células do melanoma B16-F10. A inibição farmacológica da IDO promoveu redução do crescimento tumoral nos camundongos que sobreviveram à sepse, por um mecanismo dependente da redução na diferenciação das Tregs e das células C11b+ Ly6G+ no baço e da ativação de células CD8+ produtoras de IFN- ?, no linfonodo drenate da região tumoral. Adicionalmente, foi demonstrado que, o receptor de hidrocarbonetos de arila (AhR) está associado ao aumento da expressão da IDO, nos camundongos que sobreviveram à sepse. Ainda, os resultados demonstraram que células CD11C+ são as principais responsáveis por expressar a IDO no baço de camundongos que sobreviveram à sepse. Por fim, células CD11C+ isoladas do baço de camundongos que sobreviveram a sepse, foram mais efetivas em induzir a diferenciação das Tregs quando comparadas a células CD11C+ provenientes de camundongos naive. Em conjunto, os resultados sugerem que a ativação do AhR pela quinurenina é importante para expressão da IDO nas células CD11C+ encontradas no baço de camundongos que sobreviveram à sepse, o que por sua vez, está associado com a expansão das Tregs e com o desenvolvimento do quadro de imunossupressão. / Immunosuppression has been shown to be one long-term sequels of severe sepsis, which is mainly characterized by the expansion of regulatory T cells (Tregs). However, the mechanisms underlying Tregs expansion after sepsis remain poor understood. Indoleamine 2,3-dioxygenase (IDO), an enzyme that initiates the kynurenine pathway of tryptophan degradation, has been implicated in promoting Tregs generation. Therefore, we propose to investigate the role of IDO in the development of sepsis-induced immunosuppression. The results presented here demonstrated that there is an increase in both IDO protein expression and IDO enzymatic activity in spleen of sepsis-surviving mice. Employing a melanoma mouse model as a second challenge in sepsis-surviving mice, we found that pharmacological inhibition of IDO suppressed the enhanced tumor growth observed in sepsis-surviving mice. Importantly, inhibition of IDO decreased the expansion of Tregs in sepsis-surviving mice, leading to reduced CD11b+ Ly6G+ cells frequency in spleen and activation of INF-? production by CD8+ in draining lymph, after tumor challenge. Moreover, the results suggest that aryl hydrocarbon receptor (AhR) is associated with increased IDO expression found in sepsis-surviving mice. Furthermore, we identified that a CD11C+ population of cells are expressing IDO in spleen of sepsis surviving mice. In addition, CD11C+ cells isolated from spleen of sepsis-surviving mice, presented a higher capacity to induce a regulatory phenotype in naïve CD4+ CD25- T than CD11C+ isolated from naïve mice. Taken together, our results suggest that AhR activation by kynurenine during acute phase of sepsis is important to IDO expression in a specific CD11C+. This new sepsis-induced CD11C+ IDO+ population is important to Treg cells expansion and immunosuppression development in sepsis-surviving mice.

Transmis par les moustiques, le virus de la fièvre de la vallée du Rift (vFVR) est un virus zoonotique qui affecte principalement les ruminants en Afrique et conduit à des pertes économiques importantes. Il n’existe actuellement pas de traitements et les seuls vaccins disponibles sont à usage vétérinaire. Le développement de nouveaux vaccins plus sûrs contre le vFVR est une priorité de l’OMS en raison du risque d’émergence de cet arbovirus dans d’autres continents. Dans cette étude, nous avons développé une vaccination à ADN optimisée contre le vFVR qui consiste à administrer par voie cutanée un plasmide codant pour l’ectodomaine de la glycoprotéine de surface Gn du vFVR (eGn) en présence d’un plasmide adjuvant codant le GM-CSF et combinée avec une électroporation. De plus, nous avons également optimisé la vaccination à ADN en l’associant à la stratégie de ciblage des cellules dendritiques (DCs) via un plasmide qui code des fragments d’anticorps scFv fusionnés avec l’eGn dirigés contre les récepteurs DEC205 et CD11c exprimés à la surface des DCs. Les vaccins ont été testés chez le mouton, hôte naturel du virus et dans le modèle murin pour étudier les mécanismes de protection. Dans nos deux modèles d’études, l’immunisation par le plasmide codant l’eGn confère une meilleure protection après une épreuve virale ainsi qu’une forte production d’anticorps non neutralisants par rapport au ciblage des DCs. En revanche, le ciblage d’eGn vers des récepteurs de DCs protège partiellement contre une épreuve virale et induit une immunogénicité différente dans les deux espèces. Nous avons confirmé le rôle protecteur de ces anticorps anti-eGn par un transfert passif dans le modèle murin et le mécanisme d’action de ces anticorps protecteurs reste encore à être déterminé. Notre étude montre pour la première fois la protection par un vaccin à ADN contre le vFVR chez le mouton. / The Rift valley fever virus (RVFV) is a mosquito-borne virus that mainly affect ruminants in Africa, resulting in economic burden. There is currently no treatment and only vaccine for veterinary use against the RVFV are available. The development of new and safer vaccine is urgently needed due to the risk of introduction of this arbovirus to other continents. In the present work, we developed an optimized DNA vaccination against RVFV using a plasmid encoding the ectodomain of surface glycoprotein Gn (eGn) of RVFV into the skin with plasmid adjuvant encoding GM-CSF and electroporation in sheep. We further optimized the DNA vaccination using dendritic cell targeting strategy with a plasmid encoding a single chain fragment variable (scFv) fused with eGn directed to two DC receptors, DEC205 and CD11c. The efficacy of the vaccines were tested in the sheep, the natural host and in the mouse model to investigate the mechanism of protection. In both models non-targeted eGn vaccine confer a better clinical protection and higher non-neutralizing antibody production than DC-targeted vaccine. However, in both models eGn targeting to DEC205 differentially affected the immune response and induced a partial protection after a challenge. We further demonstrated that non-neutralizing antibodies induced by native eGn protect mice by passive transfer. The mechanism mediated by these antibodies remains to be investigated. Overall, this work indicates the proof of concept that DNA vaccine can confer protection against the RVFV in the sheep.

Mast cell progenitors originate from the bone marrow and migrate to the lungs via the blood. During maturation, these cells acquire granules that contain a potent array of bronchoconstrictive mediators. The number of pulmonary mast cells is augmented in asthmatic patients and in mice with allergic airway inflammation, possibly contributing to airway hyperreactivity. An increase in mast cells is likely due to an increased recruitment of committed mast cell progenitors from the blood. However, until now a committed mast cell progenitor population has not been found in adult peripheral blood. We isolated Lin- c-kithi ST2+ integrin β7hi CD16/32hi progenitors from murine blood and showed that these cells were committed to the mast cell lineage. Based on the expression of FcεRI, these cells were less mature in Th1-prone C57BL/6 mice than in Th2-prone BALB/c mice. Asthma is associated with elevated levels of IgE. Upon exposure to allergens, IgE immune complexes are formed. In a mouse model of allergic airway inflammation, we showed that intranasal administration of IgE immune complexes to antigen-sensitized mice resulted in an increased number of mast cell progenitors compared with antigen administration alone. The increase in mast cell progenitors was independent of the low-affinity IgE receptor CD23. Rather, signaling through the common FcRγ-chain was required to enhance the number of lung mast cell progenitors. Signaling through FcεRI was likely responsible for the increase. However a role for FcγRIV could not be excluded. CD11c+ cells, such as dendritic cells, are important for antigen sensitization. In a mouse model of allergic airway inflammation, these cells are also important for the development of airway hyperreactivity, eosinophilia and Th2 cytokine production in response to antigen challenge. We showed that CD11c+ cells are critical for the recruitment of lung mast cell progenitors and the subsequent increase in mast cells. These CD11c+ cells were needed for the upregulation of endothelial vascular cell adhesion molecule-1 (VCAM-1), which is a prerequisite for the antigen-induced recruitment of lung mast cell progenitors.

Monocyte recruitment promotes the accumulation of myeloid foam cells in early atherosclerotic plaques. However, initial foam cells form prior to increased monocyte recruitment in hypercholesterolemic Ldlr-/- mice. These initial foam cells are derived from myeloid cells residing in the normal intima, and express integrin alphaX (CD11c). The goal of this thesis was to assess the role of initial foam cells in atherogenesis. The approach was to delete these cells by diphtheria toxin-induced apoptosis in Ldlr-/- bone marrow chimeras. Depletion of CD11c+ leukocytes resulted in significant reductions of intimal lipid accumulation, monocyte recruitment, intimal chemokine expression, but not endothelial cell adhesion molecule expression, at 10 and 21 days of hypercholesterolemia. These data suggest that lipid uptake by resident intimal CD11c-expressing myeloid cells during the earliest stages of atherosclerosis promotes chemokine production that is required for increased monocyte recruitment.

Monocyte recruitment promotes the accumulation of myeloid foam cells in early atherosclerotic plaques. However, initial foam cells form prior to increased monocyte recruitment in hypercholesterolemic Ldlr-/- mice. These initial foam cells are derived from myeloid cells residing in the normal intima, and express integrin alphaX (CD11c). The goal of this thesis was to assess the role of initial foam cells in atherogenesis. The approach was to delete these cells by diphtheria toxin-induced apoptosis in Ldlr-/- bone marrow chimeras. Depletion of CD11c+ leukocytes resulted in significant reductions of intimal lipid accumulation, monocyte recruitment, intimal chemokine expression, but not endothelial cell adhesion molecule expression, at 10 and 21 days of hypercholesterolemia. These data suggest that lipid uptake by resident intimal CD11c-expressing myeloid cells during the earliest stages of atherosclerosis promotes chemokine production that is required for increased monocyte recruitment.

A icterícia por hiperbilirrubinemia indireta afeta mais de 60% dos recém-nascidos a termo. O tratamento, quando necessário, é realizado através da fototerapia. Não existem estudos na literatura avaliando os efeitos da fototerapia na função dos neutrófilos de recém-nascidos. O melhor entendimento da função dos neutrófilos nos recém-nascidos antes e após a fototerapia seria importante para avaliar as possíveis repercussões na expressão dos neutrófilos desencadeadas pelo tratamento fototerápico. O objetivo deste estudo foi avaliar e comparar a função dos neutrófilos, através da mensuração pela citometria de fluxo da expressão dos principais marcadores de superfície em recémnascidos ictéricos, antes e após 24 horas de fototerapia. Metodologia: Foram incluídos recém-nascidos com idade gestacional ≥ 35 semanas e peso de nascimento ≥ 2000g, que possuiam critérios da Academia Americana de Pediatria para tratamento fototerápico. Os critérios de exclusão foram: mal-formações congênitas, síndromes com alterações cromossômicas, erro inato do metabolismo, infecções do grupo STORCH, asfixia neonatal, sepse ou suspeita de sepse, exsanguineotransfusão, transfusão de hemocomponentes e uso de imunoglobulina. Foi realizada a avaliação de expressão da intensidade média de fluorescência (IMF) de CD10, CD11b, CD11c, CD15, CD16, CD18, CD62L, CD64 e CD66, antes do início e após 24 horas do início da fototerapia. Foram utilizados o teste T de Student para análise dos dados. Resultados: Foram incluídos 25 recém-nascidos no estudo, com idade mediana de 53 (27.5-75.5) horas de vida e bilirrubina média de 13.6±2.85 mg/dL. Não houve diferença estatística na expressão de CD11b, CD15, CD18, CD62L, CD64 e percentual de neutrófilos antes e após 24 horas de fototerapia. Ocorreu aumento da expressão de CD10 8 (p=0.038) e CD16 (p=0.017) e redução da expressão de CD11c (p=0.023) e CD66acde (p=0.004) após 24 horas de fototerapia. Conclusão: Os recém-nascidos submetidos ao tratamento fototerápico apresentaram aumento da expressão de CD10 e de CD16 e diminuição da expressão de CD11c e de CD66acde após 24 horas de exposição, que pode estar relacionado a um efeito antiinflamatório da fototerapia nos recém-nascidos expostos a este tratamento. / Jaundice due to indirect hyperbilirubinemia affects more than 60% of term neonates. The treatment when necessary is carried out using phototherapy. There are no studies in the literature evaluating the effect of phototherapy on the function of neonates' neutrophils. A better understanding of the function of neutrophils in neonates before and after phototherapy would be important in order to assess potential effects on the expression of neutrofils triggered by the phototherapy treatment. The aim of this study was to assess and compare the function of neutrophils by measuring the expression of the main surface markers in icteric neonates, using flow cytometry, before and after 24 hours of phototherapy. Methodology: Neonates at a gestational age ≥ 35 weeks and at a birth weight ≥ 2000g who met the criteria of the American Academy of Pediatrics for phototherapy were included. The exclusion criteria were: congenital malformations, syndromes with chromosomal alterations, inborn errors of metabolism, infections of the STORCH group, neonatal asphyxia, sepsis or suspicion of sepsis, exchange transfusion, transfusion of blood components, and use of immunoglobulin. The evaluation of the MFI expression of CD10, CD11b, CD11c, CD15, CD16, CD18, CD62L, CD64 and CD66 was performed before and 24 hours after the initiation of phototherapy. The chi-square and Student T tests were used for data analysis. Results: Twenty-five neonates were included in the study at the mean age of 53 (27.5- 75.5) hours of life and with a mean bilirubin level of 13.6±2.85 mg/dL. There was no statistical difference in the expression of CD11b, CD15, CD18, CD62L, CD64 and percentage of neutrophils before and after 24 hours of phototherapy. There was an increase in the expression of CD10 (p=0.038) and CD16 (p=0.017) and a reduction in 10 the expression of CD11c (p=0.023) and CD66acde (p=0.004) after 24 hours of phototherapy. Conclusion: The newborns submitted to phototherapy had increased expression of CD10 and CD16 and decreased expression of CD11c and CD66acde after 24 hours of exposure, which may be related to an anti-inflammatory effect of phototherapy on the neonates exposed to this treatment.